RACHEL RAGER: Open Payments
NPI 1841505377 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,694 in 92 payments from 18 companies in 2025. Trend: 2023 $1,196 · 2024 $1,239 · 2025 $1,694
Food & beverage: $1,694
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 18 | $290 |
| GENZYME CORPORATION | 12 | $275 |
| Janssen Biotech, Inc. | 11 | $189 |
| Gilead Sciences, Inc. | 8 | $153 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $145 |
| Regeneron Healthcare Solutions, Inc. | 4 | $94 |
| Lilly USA, LLC | 4 | $80 |
| ABBVIE INC. | 4 | $77 |
| Ardelyx, Inc. | 4 | $76 |
| Ipsen Biopharmaceuticals, Inc | 3 | $66 |
Products named: DUPIXENT, REZDIFFRA, TREMFYA, ENTYVIO, OMVOH, IBSRELA, IQIRVO, RINVOQ.
Industry payments across NE — which companies pay providers there.
